Vivek Narayan

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 24 papers. Top paper: “A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial”.

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

The Lancet(2021)10.1016/s0140-6736(21)00152-5

N/A

6.9DataRank · unranked

283 citations

Catherine M. Tangen, Ian M. Thompson, Naomi Balzer-Haas, Daniel J. George, Daniel Y.C. Heng +15 more

Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial

Cancer Cell(2020)10.1016/j.ccell.2020.08.007

N/A

4.8DataRank · unranked

398 citations

Russell K. Pachynski, Vivek Narayan, Aude Fléchon, Gwénaëlle Gravis, Matthew D. Galsky +10 more

Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study

The Lancet Oncology(2024)10.1016/s1470-2045(24)00389-9

N/A

1.0DataRank · unranked

37 citations

Ane B. Iversen, Vivek Narayan, Benjamin L Maughan, Kathryn E. Beckermann, Stéphane Oudard +10 more

Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study

The Lancet Oncology(2025)10.1016/s1470-2045(25)00099-3

N/A

0.741DataRank · unranked

27 citations

Othon Iliopoulos, Kathryn E. Beckermann, Vivek Narayan, Benjamin L Maughan, Stéphane Oudard +9 more

Bearing allostatic load: insights into a more equitable future within cardio-oncology

Trends in Molecular Medicine(2022)10.1016/j.molmed.2022.09.006

N/A

0.537DataRank · unranked

9 citations

Nicholas S. Wilcox, Anran Huang, Richard J. Levy, Biniyam G. Demissei, Vivek Narayan +2 more

Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and Thyroid Cancer Treated With VEGFR TKIs

Journal of the National Comprehensive Cancer Network(2023)10.6004/jnccn.2023.7047

N/A

0.421DataRank · unranked

11 citations

Tao Liu, Xue Song, Joshua D. Mitchell, JoRean D. Sicks, Ilana F. Gareen +10 more

Risk-guided cardioprotection with carvedilol in patients with breast cancer (CCT guide): a phase 1 randomized clinical trial

Breast Cancer Research and Treatment(2025)10.1007/s10549-025-07636-3

N/A

0.208DataRank · unranked

3 citations

Rebecca A. Hubbard, Amanda M. Smith, Kyunga Ko, Anran Huang, Jessica Wang +18 more

Biomarker-Guided Cardioprotection for Patients Treated With Anthracyclines

JAMA Network Open(2025)10.1001/jamanetworkopen.2025.46201

N/A

0.208DataRank · unranked

3 citations

Amanda M. Smith, Bénédicte Lefebvre, Faizi Jamal, Saro H. Armenian, Daniel Koropeckyj-Cox +21 more

Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes

Prostate Cancer and Prostatic Diseases(2024)10.1038/s41391-024-00797-0

N/A

0DataRank · unranked

23 citations

Allison Makovec, Andrew Elliott, Samuel Kellen, John R. Lozada, Ali T. Arafa +19 more

The PRC2.1 subcomplex opposes G1 progression through regulation of CCND1 and CCND2

eLife(2024)10.7554/elife.97577

N/A

0DataRank · unranked

3 citations

Kyle Wang, Harsha Garadi Suresh, Mythili Ketavarapu, Henry N. Ward, Ian Jones +10 more

The PRC2.1 Subcomplex Opposes G1 Progression through Regulation of CCND1 and CCND2

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.03.18.585604

N/A

0DataRank · unranked

0 citations

Kyle Wang, Harsha Garadi Suresh, Mythili Ketavarapu, Henry N. Ward, Ian Jones +10 more

Reviewer #3 (Public Review): The PRC2.1 Subcomplex Opposes G1 Progression through Regulation of CCND1 and CCND2

(2024)10.7554/elife.97577.1.sa0

N/A

0DataRank · unranked

0 citations

Kyle Wang, Harsha Garadi Suresh, Mythili Ketavarapu, Henry N. Ward, Ian R. Jones +10 more

Reviewer #2 (Public Review): The PRC2.1 Subcomplex Opposes G1 Progression through Regulation of CCND1 and CCND2

(2024)10.7554/elife.97577.1.sa1

N/A

0DataRank · unranked

0 citations

Kyle Wang, Harsha Garadi Suresh, Mythili Ketavarapu, Henry N. Ward, Ian R. Jones +10 more

Reviewer #1 (Public Review): The PRC2.1 Subcomplex Opposes G1 Progression through Regulation of CCND1 and CCND2

(2024)10.7554/elife.97577.1.sa2

N/A

0DataRank · unranked

0 citations

Kyle Wang, Harsha Garadi Suresh, Mythili Ketavarapu, Henry N. Ward, Ian R. Jones +10 more

The PRC2.1 Subcomplex Opposes G1 Progression through Regulation of CCND1 and CCND2

eLife(2024)10.7554/elife.97577.1

N/A

0DataRank · unranked

0 citations

Kyle Wang, Harsha Garadi Suresh, Mythili Ketavarapu, Henry N. Ward, Ian Jones +10 more

Cardiac Effects of Modern Breast Radiation Therapy in Patients Receiving Systemic Cancer Therapy

JACC CardioOncology(2025)10.1016/j.jaccao.2025.01.012

N/A

0DataRank · unranked

12 citations

Kyunga Ko, Lin Ma, Ian Messing, Casey Hollawell, Amanda M. Smith +19 more

Enhancing Radiation Therapy Response in Prostate Cancer Through Metabolic Modulation by Mito-Lonidamine: A 1H and 31P Magnetic Resonance Spectroscopy Study

International Journal of Molecular Sciences(2025)10.3390/ijms26020509

N/A

0DataRank · unranked

0 citations

Pradeep Kumar Gupta, Fernando Arias‐Mendoza, Dinesh Kumar Singh, Skyler Nova, David Nelson +7 more

Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease

Journal of the American College of Cardiology(2020)10.1016/j.jacc.2020.03.067

N/A

0DataRank · unranked

98 citations

Elizabeth Thompson, Biniyam G. Demissei, Jennifer E. Ho, James L. Januzzi, Bonnie Ky +1 more

Assessment and management of cardiovascular risk factors among U.S. Veterans with newly diagnosed prostate cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5510

N/A

0DataRank · unranked

1 citations

Ravi B. Parikh, Kyle Robinson, Samuel U Takvorian, David J. Vaughn, Vivek Narayan +2 more

Paraoxonase-1 Activity in Breast Cancer Patients Treated With Doxorubicin With or Without Trastuzumab

JACC Basic to Translational Science(2021)10.1016/j.jacbts.2021.10.010

N/A

0DataRank · unranked

14 citations

Biniyam G. Demissei, Amanda M. Smith, Priya Brahmbhatt, Jessica Wang, Amy S. Clark +10 more

Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.270

N/A

0DataRank · unranked

9 citations

Catherine M. Tangen, Ian M. Thompson, Naomi B. Haas, Daniel J. George, Daniel Yick Chin Heng +15 more

Metastatic renal cell carcinoma to the pancreas and other sites—a multicenter retrospective study

EClinicalMedicine(2023)10.1016/j.eclinm.2023.102018

N/A

0DataRank · unranked

26 citations

Junxiao Hu, Benoit Beuselinck, Justine Panian, Nicole Weise, Nazlı Dizman +23 more

Validation of Biomechanical Computed Tomography for Fracture Risk Classification in Metastatic Hormone-sensitive Prostate Cancer

European Urology Oncology(2023)10.1016/j.euo.2023.10.016

N/A

0DataRank · unranked

12 citations

Caleb Hearn, Emily Getzen, Qi Long, David C. Lee, Tony M. Keaveny +14 more

Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2592

N/A

0DataRank · unranked

28 citations

Eric Jonasch, Othon Iliopoulos, Kathryn E. Beckermann, Vivek Narayan, Benjamin L. Maughan +10 more